Share-Based Compensation (Details) - $ / shares	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Exercised	0	(761,000)
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Dividend yield	1.80%
Expected volatility	23.30%
Risk-free interest rate	1.30%
Expected holding period	4 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Options outstanding at beginning of period	12,107,106
Options outstanding at beginning of period, weighted average exercise price	$ 11.63
Granted	2,036,010
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$ 23.00
Exercised	2,421,740
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price	$ 11.13
Options outstanding at end of period	11,721,376
Options outstanding at end of period, weighted average exercise price	$ 13.69
Options exercisable at March 31, 2012	7,517,834
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price	$ 10.33
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested [Roll Forward]
Nonvested restricted shares at beginning of period	1,319,260
Nonvested restricted shares at beginning of period, weighted average grant date fair value	$ 13.39
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	253,791
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 23.00
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period	(987,684)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value	$ 12.35
Nonvested restricted shares at end of period	585,367
Nonvested restricted shares at end of period, weighted average grant date fair value	$ 19.32